Mainolfi stated, "We shared outstanding results from both our Phase I healthy volunteer study and our Phase Ib study in AD patients... KT-621 has the potential to deliver robust efficacy in line with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results